Drug Profile



Latest Information Update: 03 Jan 2017

Price : $50

At a glance

  • Originator Isis Pharmaceuticals
  • Developer Akcea Therapeutics; Ionis Pharmaceuticals
  • Class Antihyperlipidaemics; Antisense oligonucleotides; Antisense RNA
  • Mechanism of Action Apolipoprotein C-III inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hyperlipoproteinaemias; Lipodystrophy
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Hyperlipoproteinaemia type I; Hypertriglyceridaemia; Lipodystrophy
  • Preclinical Cardiovascular disorders

Most Recent Events

  • 19 Dec 2016 Interim efficacy and adverse event data from a phase III COMPASS trial in Hypertriglyceridaemia released by Akcea Therapeutics
  • 06 Dec 2016 Phase-II/III clinical trials in Lipodystrophy in Turkey (SC) (NCT02527343)
  • 21 Sep 2016 Ionis Pharmaceuticals and Akcea Therapeutics plan a phase I trial in Healthy volunteers in USA (SC and IV) (NCT02910635)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top